Clin Surg | Volume 7, Issue 1 | Case Report | Open Access

Combination of Amineptine and Gefitinib Overcome Acquired Resistance in T790M/trans-C797S-EGFRMutated Non-Small Cell Lung Cancer: A Case Report

Huibin Lv1, Shilei Zhao1, Jinguang Wang1 and Liu Yin2*

1Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, China
2Department of Oncology, The First Affiliated Hospital of Dalian Medical University, China

*Correspondance to: Liu Yin 

Fulltext PDF

Abstract

Osimertinib, a third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs), is the second-line treatment of choice for lung cancer patients who develop T790M mutation resistance after treatment with EGFR-TKIs, but resistance still inevitably occurs after use, and the mechanism of resistance and the choice of treatment regimen after resistance remain unclear. We report a case of right lung adenocarcinoma with intrapulmonary Metastasis (pT2N0M1b, stage IV) that developed T790M/trans-C797S-EGFR-mutate after and to provide clinical evidence of EGFR-TKIs in the treatment of lung cancer and to provide reference for future studies on the treatment of similar cases and the mechanism of resistance to Osimertinib.

Citation:

Lv H, Zhao S, Wang J, Yin L. Combination of Amineptine and Gefitinib Overcome Acquired Resistance in T790M/trans-C797SEGFR- Mutated Non-Small Cell Lung Cancer: A Case Report. Clin Surg. 2022; 7: 3585..

Subscribe to Our Newsletter